Vident Advisory LLC Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vident Advisory LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 228.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,677 shares of the biopharmaceutical company’s stock after buying an additional 3,254 shares during the period. Vident Advisory LLC’s holdings in Regeneron Pharmaceuticals were worth $3,332,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. Avalon Trust Co acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Crowley Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC boosted its holdings in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 3.1%

Regeneron Pharmaceuticals stock opened at $614.79 on Wednesday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market cap of $66.38 billion, a PE ratio of 16.06, a P/E/G ratio of 2.34 and a beta of 0.43. The stock has a 50-day moving average price of $596.79 and a 200 day moving average price of $679.72. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the firm earned $9.55 EPS. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.57%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on REGN shares. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 22nd. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an “overweight” rating for the company in a report on Wednesday, April 30th. BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an “outperform” rating for the company in a report on Wednesday, April 30th. Finally, Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $890.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.